China
Africa
Explore chapters and articles related to this topic
Prevention and Treatment of Dermatological Secondary Effects of Cancer Therapy
Published in Paloma Tejero, Hernán Pinto, Aesthetic Treatments for the Oncology Patient, 2020
Some therapies can cause hypertrichosis and trichomegaly, a rare adverse effect that can develop 2–5 months after starting treatment with targeted therapies, which may persist for the duration of the treatment. For trichomegaly, it is recommended to cut the eyelashes to avoid corneal irritation; for hypertrichosis, laser hair removal is recommended once the oncological treatment is finished and the skin has recovered all its vitality [9].
Hair and Nail Manifestations of HIV Infection
Published in Clay J. Cockerell, Antoanella Calame, Cutaneous Manifestations of HIV Disease, 2012
Gabriela M. Blanco, Frankie G. Rholdon, Clay J. Cockerell
Trichomegaly refers to abnormal lengthening of the eyelashes (207). It is usually seen in congenital diseases such as Oliver–McFarlane syndrome but it may also occur acquired from drugs, malnutrition, and chronic liver disease among others. In 1987, Casanova et al.47 and Janier et al.48 first independently reported elongation of eyelashes in patients with HIV infection. Long eyelashes have also been seen in several children with acquired immunodeficiency syndrome (AIDS).49,50 Of importance is the notion that it may be a marker of late-stage disease in HIV infection.7,51–54
Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review
Published in Orbit, 2023
Adam P. Deveau, Flávia Nagel da Silva, Thai Yen Ly, Ahsen Hussain
PGF2a analogs offer an effective IOP lowering treatment for open-angle glaucoma and are generally well tolerated. Side effects from treatment include PAP, hyperemia, trichomegaly, and hyperpigmentation. The onset of these effects remains variable and is considered largely reversible once the medication has been discontinued. Therefore, patient education should be considered before the administration of therapy. Including our patient, there are now two case reports that demonstrate the development of melanoma associated with bimatoprost use. To our knowledge, our report is the first to describe a patient using bimatoprost who demonstrated invasive melanoma on the ipsilateral treated side in a distribution similar to drop spread. It should be noted, however, that causal association is not proven without attention to epidemiological consideration. However, this may prompt further investigation looking into patients diagnosed with melanoma and what medications they may be on, including any PGF2α analogs. Hyperpigmentation of a previously developing lesion, which came to clinical attention via bimatoprost use is also plausible. Based on our case presentation and review, we suggest that patient follow-up should specifically include examination for pre-existing periocular changes and hyperpigmentation including documentation and clinical photography. As demonstrated, in some patients using PGF2a analogs, development of new or darkening pigmentation may herald more sinister pathology requiring early recognition and management.
Oliver McFarlane syndrome: two new cases and a review of the literature
Published in Ophthalmic Genetics, 2021
Kristian Lisbjerg, Mette K. G. Andersen, Mette Bertelsen, Agnes G. Brost, Frederik F. Buchvald, Rikke B. Jensen, Anne-Marie Bisgaard, Thomas Rosenberg, Zeynep Tümer, Line Kessel
The first individual, a 36-year-old woman, was delivered at 33 weeks of gestational age by acute caesarian section by healthy unrelated parents, she was born small for gestational age (SGA) with a birthweight of 1650 g (−2.1 standard deviation (SD)). Due to neonatal respiratory distress syndrome (RDS), the girl was admitted to the pediatric department and received oxygen supplementation for four weeks before discharge. Her growth was delayed, and she had a height corresponding to −4 SD below average throughout her first years of life. No persisting respiratory symptoms, neurological problems or mental retardation was documented, but motor skills were slightly delayed. It was noted that the patient had sparse, curly, depigmented hair, a prominent forehead, and very long eyelashes (trichomegaly). Repeated ophthalmological examinations during the first year were noted as unremarkable.
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study
Published in Cutaneous and Ocular Toxicology, 2019
Basak Yalici-Armagan, Burcu Tugrul Ayanoglu, Hatice Gamze Demirdag
Hair and nail changes are the other epidermal-derived toxicities associated with EGFRIs17. The most common nail changes are nail fold inflammation (paronychia) and periungual pyogenic granuloma-like lesions29. Alterations in hair growth and texture related to EGFRI therapy are rare and usually consist of excess growth of the eyelashes and/or eyebrows (i.e. trichomegaly) or curly, wavy, fine, and brittle texture of facial and/or scalp hair. In our study, paronychia and trichomegaly of eyelashes were accompanying with the papulopustular rash in 3 (7.6%) and 2 (5.1%) patients, respectively. Periungual pyogenic granuloma-like lesion was accompanying with paronychia in one patient. These changes can cause pain and impair ADL and may necessitate dose modifications or even temporary discontinuation of the EGFRIs in severe cases.